title: Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women.
abstract: BACKGROUND
  The concordance rate between immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) results for HER2/neu according to clinical performance is controversial. The present prospective study was theerefore conducted in Indian breast cancer patients.
  
  
  METHODS
  Fifty cases (n=50) of invasive duct cancer of breast tested for HER-2/neu by IHC and scored as 0, 1+, 2+ and 3+ by pathologists were further analyzed by FISH using a commercially available double-color probe, and the findings compared.
  
  
  RESULTS
  A total concordance of 82.0% was observed with a Kappa coefficient of 0.640 (P <0.001). A high discordance was observed in 30.0% of the patients with IHC 2+, 7.1% in IHC 3+, 19.2% overall in IHC 0 and 1+.
  
  
  CONCLUSIONS
  IHC can be used firstly to screen the HER-2/neu status, and FISH can be used as a supplementary role to IHC and 2+ and some negative cases. And only those cases with HER-2/neu status of IHC 3+ or FISH positive should be treated with Herceptin (Trastuzumab).
authors.affiliation: Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India. dr.rajeevj@gmail.com
authors.forename: Rajeev
authors.initials: R
authors.lastname: Singhai
authors.forename: Vw
authors.initials: V
authors.lastname: Patil
authors.forename: Av
authors.initials: A
authors.lastname: Patil
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D005260:Female; D005784:Gene Amplification; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D007194:India; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human